Pulmonary Arterial Hypertension Market by Drug Class (Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, Phosphodiesterase-5 (PDE-5) Inhibitors, and Soluble Guanylate Cyclase (sGC) Stimulators); By Application (Hospitals, Clinics, and Others); By Geography (North America, Asia-Pacific, Europe, South America, and RoW), Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028

Market Overview

The global Pulmonary Arterial Hypertension market size is estimated at 11.96 billion USD with a CAGR of 7.8% during the forecasted period from 2021-2028.

A rare disease categorized by unusually high blood pressure or hypertension in the pulmonary artery, the blood vessel that transports blood from the heart to the lungs is referred to Pulmonary Arterial Hypertension. In this medical condition, there is narrowing & blockage of arteries & capillaries. This condition can be detrimental if not treated at the right time and can also cause death.

The key factor driving the growth of this market is attributed to increasing prevalence of Pulmonary Arterial Hypertension. In addition, initiatives taken by government and various private to support the development of orphan drugs is expected to boost the growth of this market. Also, a large geriatric pool is projected to the upsurge Pulmonary Arterial Hypertension market. Moreover, changing lifestyle habits such as unhealthy dietary patterns, sedentary lifestyle, alcohol abuse, etc. is promoting the market size.

On the other hand, factors such as lack of awareness concerning pulmonary arterial hypertension among patients, and high cost of diagnosis and treatment cost are likely to limit the market growth. Also, strict guidelines by government may pose a threat to the expansion of Pulmonary Arterial Hypertension market.

Market Dynamics

Increasing prevalence of PAH disorder owing to rising risk factors such as sedentary lifestyle, consumption of tobacco and alcohol, smoking, and other idiopathic conditions propels the growth of the global pulmonary arterial hypertension market. Various breakthrough therapies for treatment of pulmonary arterial hypertension, government support for the development of orphan drugs, and increasing geriatric population are other major growth stimulants for the Europe carpet market. However, expiry of patents of major pulmonary arterial drugs such as Letiaris, Tyvaso, Tracleer, and Adcirca may hamper the market from growing. Moreover, Favorable policies by government is likely to gain significant impetus for the pulmonary arterial hypertension market share in the coming years.

Market Segmentation

The study provides a crucial view of the pulmonary arterial hypertension by segmenting the market based on the drug class, application, and geography. By drug class segment, the segmentation comprises of endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators. Hospitals, clinics, and others are the classification of the application segment. Furthermore, geographical coverage has been offered for each of the major regions including North America, Asia-Pacific, Europe, Row, and South America.

Scope of the Global Pulmonary Arterial Hypertension Market

By Drug Class

• Endothelin Receptor Antagonists (ERAs)
• Prostacyclin and Prostacyclin Analogs
• Phosphodiesterase-5 (PDE-5) Inhibitors
• Soluble Guanylate Cyclase (sGC) Stimulators

By Application

• Hospitals
• Clinics
• Other Applications

By Geography

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Korea
  • Rest of APAC
• South America
  • Brazil
  • Rest of South America
• Rest of the World
  • Middle East
  • Africa

TABLE OF CONTENTS

Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Market Scope

Chapter 2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources

Chapter 3 Market Overview
3.1 Report Segmentation & Scope
3.2 Key Market Trends
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.3 Porter’s Five Forces Analysis
3.4 Market Share Analysis

Chapter 4 Global Pulmonary Arterial Hypertension Market by Drug Class: Market Size and Forecast, 2018 – 2026
4.1 Introduction
4.1.1 Market Size and Forecast
4.2 Endothelin Receptor Antagonists (ERAs)
4.2.1 Market Size and Forecast
4.3 Prostacyclin and Prostacyclin Analogs
4.3.1 Market Size and Forecast
4.4 Phosphodiesterase-5 (PDE-5) Inhibitors
4.4.1 Market Size and Forecast
4.5 Soluble Guanylate Cyclase (sGC) Stimulators
4.5.1 Market Size and Forecast

Chapter 5 Global Pulmonary Arterial Hypertension Market by Application: Market Size and Forecast, 2018 – 2026
5.1 Introduction
5.1.1 Market Size and Forecast
5.2 Hospitals
5.2.1 Market Size and Forecast
5.3 Clinics
5.3.1 Market Size and Forecast
5.4 Other Applications
5.4.1 Market Size and Forecast

Chapter 6 Global Pulmonary Arterial Hypertension Market by Geography: Market Size and Forecast, 2018 – 2026
6.1 Introduction
6.1.1 Market Size and Forecast
6.2 North America
6.2.1 North America Market Size & Forecast, By Country
6.2.2 North America Market Size & Forecast, By Drug Class
6.2.3 North America Market Size & Forecast, By Application
6.2.4 The U.S.
6.2.4.1 Market Size and Forecast
6.2.5 Canada
6.2.5.1 Market Size and Forecast
6.2.6 Mexico
6.2.6.1 Market Size and Forecast
6.3 Europe
6.3.1 Europe Market Size and Forecast, By Country
6.3.2 Europe Market Size and Forecast, By Drug Class
6.3.3 Europe Market Size and Forecast, By Application
6.3.4 UK
6.3.4.1 Market Size and Forecast
6.3.5 Germany
6.3.5.1 Market Size and Forecast
6.3.6 France
6.3.6.1 Market Size and Forecast
6.3.7 Italy
6.3.7.1 Market Size and Forecast
6.3.8 Spain
6.3.8.1 Market Size and Forecast
6.3.9 Rest of Europe
6.3.9.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Asia-Pacific Market Size and Forecast, By Country
6.4.2 Asia-Pacific Market Size and Forecast, By Drug Class
6.4.3 Asia-Pacific Market Size and Forecast, By Application
6.4.4 India
6.4.4.1 Market Size and Forecast
6.4.5 China
6.4.5.1 Market Size and Forecast
6.4.6 Australia
6.4.6.1 Market Size and Forecast
6.4.7 Japan
6.4.7.1 Market Size and Forecast
6.4.8 South Korea
6.4.8.1 Market Size and Forecast
6.4.9 Rest of Asia-Pacific
6.4.9.1 Market Size and Forecast
6.5 South America
6.5.1 South America Market Size and Forecast, By Country
6.5.2 South America Market Size and Forecast, By Drug Class
6.5.3 South America Market Size and Forecast, By Application
6.5.4 Brazil
6.5.4.1 Market Size and Forecast
6.5.5 Rest of South America
6.5.5.1 Market Size and Forecast
6.6 RoW
6.6.1 RoW Market Size and Forecast, By Country
6.6.2 RoW Market Size and Forecast, By Drug Class
6.6.3 RoW Market Size and Forecast, By Application
6.6.4 RoW Market Size and Forecast, By End-User
6.6.5 Middle East
6.6.5.1 Market Size and Forecast
6.6.6 Africa
6.6.6.1 Market Size and Forecast

Chapter 7 Company Profiles
7.1 Actelion Pharmaceuticals, Ltd.
7.2 Bayer HealthCare
7.3 Gilead Sciences, Inc.
7.4 GlaxoSmithKline Plc.
7.5 Novartis International AG
7.6 Pfizer, Inc.
7.7 United Therapeutics Corporation

Pulmonary Arterial Hypertension Market Key Players

• Actelion Pharmaceuticals, Ltd.
• Bayer HealthCare
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc.
• Novartis International AG
• Pfizer, Inc.
• United Therapeutics Corporation